Personalized Medicine in Psoriasis - A Long Road Ahead?

Area of Science:

• Immunodermatology
• Precision Medicine
• Biomarker Discovery

Background:

• Biologic therapies targeting IL-17 and IL-23 have transformed psoriasis management.
• Current psoriasis treatment selection remains largely empirical due to a lack of validated biomarkers for personalization.

Purpose of the Study:

• To address challenges in psoriasis biomarker development.
• To introduce the PICASSO prospective cohort as a platform for advancing personalized psoriasis medicine.

Main Methods:

• The PICASSO study is a 10-year prospective biobank/registry.
• It enrolls patients with psoriasis within three years of disease onset.
• Biological samples are longitudinally collected and linked to clinical/epidemiological data, with follow-ups every 2.5 years.

Main Results:

• Despite understanding IL-17/IL-23 inhibitor effects on immune cells, reliable predictive biomarkers for psoriasis are lacking.
• Barriers include complex pathogenesis, high overall biologic efficacy, inconsistent genetic/transcriptomic findings, and comorbidities.

Conclusions:

• Personalized psoriasis care necessitates biomarkers for predicting disease progression and comorbidity risk.
• The PICASSO cohort is a key initiative towards developing disease-modifying, preventive precision medicine for psoriasis.